Antibodies Neutralize Bird Flu, Other Strains

Feb. 23, 2009 -- Scientists on Sunday unveiled lab-made human antibodies that can disable several types of influenza, including highly-lethal H5N1 bird flu and the "Spanish Flu" strain that killed tens of millions in 1918.

Tested in mice, the antibodies work by binding to a previously obscure structure in the flu virus which, when blocked, sabotages the pathogen's ability to enter the cell it is trying to infect, according to the study.

Because this structure -- described by one scientist as a "viral Achilles' heel" -- is genetically stable and has resisted mutation over time, the antibodies are effective against many different strains.

The breakthrough "holds considerable promise for further development into a medical tool to treat and prevent seasonal as well as pandemic influenza," said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which helped fund the study.

Clinical trials on humans could begin within a couple of years, the researchers said.

Related Content:

• Gold Nanoparticles Resurrect Failed HIV Drug
• Discovery Tech: Expert Interviews, Video, Slide Shows and More
• HowStuffWorks.com: Pandemic Flu
• More Discovery News

Seasonal flu kills more than 250,000 people every year, and pandemic flu, which occurs with the emergence of deadly viral strains against which people lack immunity, remains an ever-present threat.

Vaccines have long been the first line of defense against flu, but even seasonal viruses evolve so rapidly that the vaccines need to be updated every year. Even then, they are not always effective.

A team led by Wayne Marasco, a professor at Harvard Medical School, began the study by scanning tens of billions of so-called monoclonal antibodies in the laboratory.

Antibodies, produced by the immune system's white blood cells, are highly specialized proteins that seek out and bind to other large molecules, called antigens, found on the surface of an invading bacteria or virus.

Once locked in, an antibody serves as a beacon to immune cells that attack the pathogens. More rarely, it can disable a disease agent all by itself.

Monoclonal antibodies are manufactured in the laboratory from a single parent cell using a technique devised more than 30 years ago.

In cancer treatment, they help the immune system zero in on the right target.